Anteris Technologies Global Corp. (AVR) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Anteris Technologies Global Corp. (AVR) surged +5.25% to $6.42, trading at 40% of its 52-week range ($3.3 – $11.06). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced that Azeem Latib, MD, will present the first 3
The presentation will report 30-day outcomes in patients with severe aortic stenosis who received the medium-size DurAVR THV in the ongoing EMBARK study. Since 2021 over 130 patients have been treated with the DurAVR
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured full German regulatory clearance for its pivotal PARADIGM trial, allowing the company to begin recruiting patients in Europe’s largest transcatheter aortic v
MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -29.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AVR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AVR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Anteris Technologies Global Corp. (AVR) ranks #778 by composite RQD confidence (36/100, grade D-) and #416 by equity capitalization ($625.9M). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. CDRE currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with AVR at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AVR
ACTIVE
Anteris Technologies Global Corp. | D- | 36/100 | — | 70.3% | -35.0% | +5.25% | $625.9M | Benchmark Subject |
| SMTI Sanara MedTech Inc. | D+ | 57/100 | 8.1x | 92.7% | 16.3% | +0.11% | $302.4M | /smti-vs-avr → |
| ENOV Enovis Corporation | D | 46/100 | — | 59.8% | -32.7% | +4.11% | $1.32B | /enov-vs-avr → |
| ZJYL JIN MEDICAL INTERNATIONAL LTD. (Class A) | D | 47/100 | — | 29.2% | — | -2.10% | $294.2M | /zjyl-vs-avr → |
| CDRE Cadre Holdings Inc. | B | 74/100 | 30.2x | 42.5% | 11.0% | +3.81% | $1.33B | /cdre-vs-avr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anteris Technologies Global Corp. (AVR) reported GAAP revenue of $1.9M (-29.2% vs. FY2024 revenue of $2.7M ) , GAAP net income of -$94.1M, operating cash flow of -$77.8M, and free cash flow of -$79.8M (-25.6% YoY). On the balance sheet, AVR closed FY2025 with $23.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.9M | -$94.1M | -$77.8M | -$79.8M | $23.0M | — |
| FY2024 (FY) | 2024-12-31 | $2.7M | -$76.3M | -$61.2M | -$63.5M | $80.7M | — |
As of 2026-11-01, Anteris Technologies Global Corp. (NASDAQ: AVR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $6.42 (+5.25% 1D, market cap $625.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AVR ranks #778 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), AVR carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 70.3%, and ROIC of -35.0%. By comparison, SMTI (Sanara MedTech Inc.) holds a D+ grade (57/100 RQD, P/E 8.1x, ROIC 16.3%, cap $302.4M) and ENOV (Enovis Corporation) posts a D grade (46/100 RQD, P/E N/A, ROIC -32.7%, cap $1.32B). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
Per AVR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002011514), Anteris Technologies Global Corp. generated $1.9M in revenue (-29.2% YoY), -$94.1M in net income, and -$79.8M in free cash flow against $23.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
AVR last traded at $6.42 (+5.25% on volume of 2,822,317 shares), positioning the stock -15.08% below its 50-day simple moving average ($7.56) and -13.13% below its 200-day simple moving average ($7.39). Across its 52-week range of $3.30 to $11.06, AVR sits at the 40.2% percentile with a 14-day RSI of 41.3 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($5.74 to $7.10).
Why AVR Stock surged +5.25% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.